Prima BioMed Gross Margin 2010-2021 | IMMP
Current and historical gross margin for Prima BioMed (IMMP) over the last 10 years. The current gross profit margin for Prima BioMed as of December 31, 2021 is %.
|Prima BioMed Gross Margin Historical Data
||TTM Gross Profit
||Medical - Biomedical and Genetics
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.